The Relative Distribution of Membranous and Cytoplasmic Met Is a Prognostic Indicator in Stage I and II Colon Cancer

Purpose: The association hepatocyte growth factor receptor (Met) tyrosine kinase with prognosis and survival in colon cancer is unclear, due in part to the limitation of detection methods used. In particular, conventional chromagenic immunohistochemistry (IHC) has several limitations including the inability to separate compartmental measurements. Measurement of membrane, cytoplasm, and nuclear levels of Met could offer a superior approach to traditional IHC. Experimental Design: Fluorescent-based IHC for Met was done in 583 colon cancer patients in a tissue microarray format. Using curvature and intensity-based image analysis, the membrane, nuclear, and cytoplasm were segmented. Probability distributions of Met within each compartment were determined, and an automated scoring algorithm was generated. An optimal score cutpoint was calculated using 500-fold crossvalidation of a training and test data set. For comparison with conventional IHC, a second array from the same tissue microarray block was 3,3′-diaminobenzidine immunostained for Met. Results: In crossvalidated and univariate Cox analysis, the membrane relative to cytoplasm Met score was a significant predictor of survival in stage I (hazard ratio, 0.16; P = 0.006) and in stage II patients (hazard ratio, 0.34; P ≤ 0.0005). Similar results were found with multivariate analysis. Met in the membrane alone was not a significant predictor of outcome in all patients or within stage. In the 3,3′-diaminobenzidine–stained array, no associations were found with Met expression and survival. Conclusions: These data indicate that the relative subcellular distribution of Met, as measured by novel automated image analysis, may be a valuable biomarker for estimating colon cancer prognosis.

[1]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[2]  M. Weiser,et al.  Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. , 2007, Cancer letters.

[3]  G. Condorelli,et al.  Insulin-like Growth Factor-I Receptor Internalization Regulates Signaling via the Shc/Mitogen-activated Protein Kinase Pathway, but Not the Insulin Receptor Substrate-1 Pathway* , 1998, The Journal of Biological Chemistry.

[4]  R. Simon,et al.  A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. , 1996, Statistics in medicine.

[5]  Roderick Turner,et al.  c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  S. Schmid,et al.  Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis , 1996, Science.

[7]  W. Hohenberger,et al.  High‐risk groups of patients with Stage II colon carcinoma , 2001, Cancer.

[8]  I. Tsarfaty,et al.  Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. , 2000, Cytometry.

[9]  D. Rimm,et al.  Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. , 2006, Cancer research.

[10]  H. Kanetake,et al.  Presence of Phosphorylated Hepatocyte Growth Factor Receptor/c-Met Is Associated with Tumor Progression and Survival in Patients with Conventional Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[11]  Madhu Mazumdar,et al.  Methods for categorizing a prognostic variable in a multivariable setting , 2003, Statistics in medicine.

[12]  F. Schmitz,et al.  Functional Expression of HGF and Its Receptor in Human Colorectal Cancer , 2000, Digestion.

[13]  Torsten Hothorn,et al.  On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..

[14]  J. Pessin,et al.  Inhibition of Clathrin-Mediated Endocytosis Selectively Attenuates Specific Insulin Receptor Signal Transduction Pathways , 1998, Molecular and Cellular Biology.

[15]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[16]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[17]  T. Sakaki,et al.  Clinical features and management of brain arteriovenous malformations in elderly patients , 2004, Acta Neurochirurgica.

[18]  M. Schumacher,et al.  Evaluating the effect of optimized cutoff values in the assessment of prognostic factors , 1996 .

[19]  T. Karrison,et al.  Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. , 1997, Controlled clinical trials.

[20]  G. V. Vande Woude,et al.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Baljit Singh,et al.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. , 2003, Cancer research.

[22]  I. Yang,et al.  Molecular staging for survival prediction of colorectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jilin Sun,et al.  Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. , 2006, Cancer research.

[24]  D. Rimm,et al.  Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays , 2006, Clinical Cancer Research.

[25]  G. V. Vande Woude,et al.  Endosomal dynamics of Met determine signaling output. , 2003, Molecular biology of the cell.

[26]  P. Várnai,et al.  c-Met Must Translocate to the Nucleus to Initiate Calcium Signals*♦ , 2008, Journal of Biological Chemistry.

[27]  G. Woude,et al.  HGF/SF-Met signaling in tumor progression , 2005, Cell Research.

[28]  J. Laterra,et al.  Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation , 2005, Clinical Cancer Research.

[29]  J. Laterra,et al.  Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  A. Sobrero.  Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. , 2006, The Lancet. Oncology.

[31]  M. Campbell,et al.  Met Receptor Signaling: A Key Effector in Esophageal Adenocarcinoma , 2006, Clinical Cancer Research.

[32]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[34]  C. Köhne.  Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. , 2006, The Lancet. Oncology.

[35]  John O'Quigley,et al.  An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .

[36]  B. Teh,et al.  Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. , 2002, Cancer research.

[37]  D. Sargent,et al.  Current Issues in Adjuvant Treatment of Stage II Colon Cancer , 2006, Annals of Surgical Oncology.

[38]  C. Howe,et al.  NGF Signaling from Clathrin-Coated Vesicles Evidence that Signaling Endosomes Serve as a Platform for the Ras-MAPK Pathway , 2001, Neuron.

[39]  Mark von Zastrow,et al.  Signal transduction and endocytosis: close encounters of many kinds , 2002, Nature Reviews Molecular Cell Biology.

[40]  P. Parker,et al.  PKC controls HGF‐dependent c‐Met traffic, signalling and cell migration , 2004, The EMBO journal.

[41]  D. Rimm,et al.  Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors , 2003, Cancer.